Translating Cell Therapies: Academic versus Industry model

by Alexey Bersenev on August 7, 2015 · 0 comments

in conferences

Post to Twitter Send Gmail Post to LinkedIn

This is a presentation from my talk that I gave this week at the BioProcessing Summit.

In the first part, I’m sharing the latest update on value of academic vs. industry cell therapy trials. It measured as input – a number of registered clinical trials for the last 4 years, and, as output – a number of publications results of clinical studies. Take home message 1 – academics hugely outperform industry by number of cell therapy clinical studies and publications of their results.

In the second part, I highlighted differences between academic and industry models of development cell therapeutics. Take home message – these models are very different!

In the final part of the presentation, I discussed potential gaps in translation with emphasys on academic GMP cell therapy facilities. I described a few ways of interaction between academia and industry in translation of cell therapies. Finally I gave few advices to academics and industry folks on how to make translational interaction better.

You can look at, link to and cite the following graphs from the presentation:
http://dx.doi.org/10.6084/m9.figshare.1504124
http://dx.doi.org/10.6084/m9.figshare.1504131
http://dx.doi.org/10.6084/m9.figshare.1504311
http://dx.doi.org/10.6084/m9.figshare.1504586

Please feel free to discuss and share!

{ 0 comments… add one now }

Leave a Comment

Previous post:

Next post: